Disease · MONDO_0001577
Comparisons in its trials39
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 39
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Presatovir vs Placebo: deaths from any cause | 2 of 92 | 0 of 94 | 186 | NCT02135614 | Trial comparisons |
| Presatovir vs Placebo: serious adverse events | 8 of 92 | 13 of 94 | 186 | NCT02135614 | Trial comparisons |
| Presatovir vs Placebo: deaths from any cause | 2 of 95 | 4 of 90 | 185 | NCT02254408 | Trial comparisons |
| Presatovir vs Placebo: serious adverse events | 18 of 95 | 23 of 90 | 185 | NCT02254408 | Trial comparisons |
| Combined EDP-938 vs Combined Placebo: Pooled Population: Number of Participants Who Experienced a TEAE | 28 of 70 | 13 of 26 | 96 | NCT04816721 | Trial comparisons |
| EDP-938 vs Placebo: Number of Participants With Adverse Events | 11 of 40 | 11 of 41 | 81 | NCT04196101 | Trial comparisons |
| EDP-938 vs Placebo: deaths from any cause | 0 of 40 | 0 of 41 | 81 | NCT04196101 | Trial comparisons |
| EDP-938 vs Placebo: serious adverse events | 0 of 40 | 0 of 41 | 81 | NCT04196101 | Trial comparisons |
| Presatovir vs Placebo: deaths from any cause | 0 of 40 | 0 of 20 | 60 | NCT02534350 | Trial comparisons |
| Presatovir vs Placebo: serious adverse events | 2 of 40 | 4 of 20 | 60 | NCT02534350 | Trial comparisons |
| Presatovir vs Placebo: deaths from any cause | 0 of 30 | 4 of 29 | 59 | NCT02254421 | Trial comparisons |
| Presatovir vs Placebo: serious adverse events | 7 of 30 | 7 of 29 | 59 | NCT02254421 | Trial comparisons |
| Part 1: EDP-938 vs Part 1: Placebo: Part 1: Number of Participants Who Experienced a Treatment-emergent Adverse Event (TEAE) | 14 of 36 | 9 of 16 | 52 | NCT04816721 | Trial comparisons |
| Part 2: EDP-938 vs Part 2: Placebo: Part 2: Number of Participants Who Experienced a TEAE | 14 of 34 | 4 of 10 | 44 | NCT04816721 | Trial comparisons |
| Rilematovir vs Placebo: Number of Participants With Treatment-emergent Adverse Events (TEAEs) | 11 of 20 | 5 of 8 | 28 | NCT04583280 | Trial comparisons |
| Rilematovir vs Placebo: deaths from any cause | 0 of 20 | 0 of 8 | 28 | NCT04583280 | Trial comparisons |
| Rilematovir vs Placebo: serious adverse events | 1 of 20 | 0 of 8 | 28 | NCT04583280 | Trial comparisons |
| Rilematovir vs Placebo: Number of Participants With Post-baseline RSV-related Complications | 3 of 19 | 1 of 8 | 27 | NCT04583280 | Trial comparisons |
| Rilematovir vs Placebo: Number of Participants With Medical Encounters and Treatments | 3 of 19 | 1 of 8 | 27 | NCT04583280 | Trial comparisons |
| JNJ-53718678 vs Placebo: deaths from any cause | 0 of 11 | 0 of 11 | 22 | NCT04068792 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0001577/comparisons